Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer
BACKGROUND Although protease‐activated receptors (PARs) have been described to play a role in different malignancies, their expression and biological activity in prostate cancer are mostly unknown. METHODS PAR expression in radical prostatectomy specimens was investigated by immunohistochemistry (IH...
Gespeichert in:
Veröffentlicht in: | The Prostate 2007-05, Vol.67 (7), p.743-756 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BACKGROUND
Although protease‐activated receptors (PARs) have been described to play a role in different malignancies, their expression and biological activity in prostate cancer are mostly unknown.
METHODS
PAR expression in radical prostatectomy specimens was investigated by immunohistochemistry (IHC, 40 patients) and RT‐PCR. Their role in LNCaP prostate cancer cell migration and Rac1/Cdc42 signaling was assessed with Boyden chamber analysis and Western blot, respectively.
RESULTS
PAR mRNA expression was higher in cancer, and protein expression was increased in PAR‐1 (45%), PAR‐2 (42%), and PAR‐4 (68%), compared to normal glands. Increased PAR‐1 (periglandular stroma) was associated with higher rates of biochemical recurrence (median follow‐up, 5 years; P = 0.006). LNCaP migration was enhanced twofold and Rac1/Cdc42 signaling was activated by stimulation of PAR‐1 and PAR‐2.
CONCLUSIONS
PARs are overexpressed in prostate cancer and may serve as potential predictors of recurrence. The data suggest potential role of PARs in autocrine and paracrine mechanisms of prostate cancer. Prostate 67: 743–756, 2007. © 2007 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0270-4137 1097-0045 |
DOI: | 10.1002/pros.20503 |